Bookmark and Share

Laundette  Jones

Laundette Jones Ph.D.

Academic Title: Assistant Professor
Primary Appointment: Epidemiology & Public Health
Secondary Appointments: Pharmacology
Location: 660 W. Redwood Street. Howard Hall, Rm. 101
Phone: (410) 706-7331

Personal History:

After receiving her bachelor's degree in Chemistry from Morgan State University, Dr. Jones earned her PhD in Environmental Health Sciences/Toxicological Sciences at the Johns Hopkins Bloomberg School of Public Health. Her postdoctoral training included a fellowship at the Laboratory of Experimental Carcinogenesis at the National Institutes of Health and a second fellowship at the Georgetown University, Lombardi Cancer Center where she investigated the role of the Breast Cancer Susceptibility (BRCA1) gene in breast cancer development. Dr. Jones was selected as a NIH BIRCWH (Building Interdisciplinary Research Careers in Women's Health) Scholar by the Women's Health Research Group at the University of Maryland School of Medicine and joined the faculty as a member of the Department of Pharmacology.

Experiments Dr. Jones’ lab worked together towards a common goal: To translate mechanistic basic research to the clinic by identifying early biomarkers associated with the development of breast cancer that could yield new targets for prevention of this disease. She has over 15+ years of experience studying how changes in endogenous and exogenous hormonal/environmental factors contribute to tumor development in preclinical mouse models of breast cancer.

Research Interests:

Currently, she is a faculty member in the Department of Epidemiology and Public Health where her basic science research background informs her research to identify environmental factors that contribute to cancer health disparities and to develop research relationships to engage with transdisciplinary teams. She is also a member of the Program in Health Disparities and Population Health Workgroup and is collaborating on an initiative led by Drs. Joanne Dorgan (UMB) and Cher Dallal (UMD) to develop the Maryland Cancer Survivorship Cohort in the Greenebaum Cancer Center to identify causes of disparities in cancer survival and quality of life outcomes. 


Selected Publications

  1. Jones, L.P., Li, M., Halama, E., Ma, Y., Lubet, R., Grubbs, C.J., Deng, C-X, Rosen, E., Furth, P.A. (2005) Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation related breast cancer. Oncogene 24: 3554-3562.
  2. Ma, Y, Katiyar, P, Jones, LP, Fan, S, Zhang, Y, Furth, PA and Rosen, EM. (2006) The Breast Cancer Susceptibility Gene BRCA1 Regulates Progesterone Receptor Signaling in Mammary Epithelial Cells. Molecular Endocrinology, 20:14-34.
  3. Herschkowitx, JI, Simin, K, Weigman, VJ, Mikaelian, I, Usary, J, Hu, Z, Rasmussen, KE, Jones, LP, Assfnia, S, Chandrasekharan, S., Backlund, MG, Yin, Y., Khramtsov, AI, Bastein, R, Quac,enbush, J, Glazer, RI, Brown, PH, Green, JE, Kopelovich, L., Furth, PA, Palazzo, JP, Olopade, OI, Bernard, PS, Churchhill, GA, Dyke, TV, and Perou, CM. (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biology, 8:R76.
  4. Tilli, M.T., Parrish, A.R., Cotarla, I., Jones, L.P. Johnson, M. and Furth, PA. (2008) Comparison of mammary gland imaging techniques and applications: reflectance confocal microscopy, GFP imaging, and ultrasound. BMC Cancer. 8:21.
  5. Bodreddigari, S*, Jones, L*, Egner, P, Groopman, J, Sutter, C, Roebuck,B, Guengerich, F., Kensler, T, and Sutter, T. (2008) Protection Against Aflatoxin B1-induced Cytotoxicity by Expression of the Cloned Aflatoxin B1-aldehyde Reductases Rat AKR7A1 and Human AKR7A3. Chem Res Toxicol. 21:1134-42 (*Equal contribution).
  6. Jones, L. P., Tilli, M.T., Assefnia, S., Torre, K., Halama, E, Parrish, A., Rosen, E. M., Furth, P. (2008) Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERa negative and ERa positive mammary preneoplasia and cancer.Oncogene. 27:794-802.
  7. Jones, LP, Sampson, A, Kang, HJ, Kim, HJ, Yi, YW, Kwon, SY, Babus, JK, Bae, I., (2010) Loss of BRCA1 leads to an increase sensitivity to Bisphenol A. Toxicology Letters, 199:261-268.
  8. Jones, LP, Stefansson, S, Kim, M, Ahn, SN. (2011) Comparison of Radioimmuno and Carbon Nanotube Field-Effect Transistor Assays for Measuring Insulin-Like Growth Factor-1 in a Preclinical Model of Human Breast Cancer. J. Nanobiotechnology, 9:36.
  9. Jones LP, Buelto D, Tago E, Owusu-Boaitey K. (2011) Abnormal mammary adipose tissue environment of Brca1 mutant mice show a persistent deposition of highly vascularized multilocular adipocytes. Journal of Cancer Science & Therapy.
  10. Cao Q, Hersl J, La H, Smith M, Jenkins J, Goloubeva O, Vasken Dilsizian,Tkaczuk K, Chen W, Jones L. (2014) A Pilot Study of FDG PET/CT Detects a Link Between Brown Adipose Tissue and Breast Cancer. BMC Cancer. 14:126.
  11. McDonald L., Jones LP, Trimbell C. (2015) Implementation of an evidence-based practice project to increase hospital-based cervical cancer screening compliance. International Journal of Nursing, 4:70-82
  12. Ivana Vucenik, Laundette P Jones and John C McLenithan (2015) Metabolic Syndrome: A Comprehensive Textbook – Contribution: Linking Obesity, Metabolism and Cancer. Springer International Publishing. pp. 723-742.
  13. Sigl V, Owusu-Boaitey K, Joshi P, Kavirayani A, Wirnsberger G, Novatchkova N, Kozieradzki I, Schramek D, Edokobi N, Hersl J, Sampson A, Odai-Afotey A, Lazaro C, Gonzalez-Suarez, Pujana M, for CIMBA, Heyn H, Vidai E, Cruickshank J, Berman H, Sarao R, Ticevic M, Uribesalgo I, Tortola L, Rao S, Tan Y, Pfeiler G, Lee E, Zsuzsanna B-H, Kenner L, Popper H, Singer C, Khokha R, Laundette P. Jones* and Josef M.Penninger*. (2016) RANKL/RANK control Brca1 mutation-driven mammary tumors Co-corresponding authors. Cell Research 26:761-774. doi: 10.1038/cr.2016.69